Human CCK8 ELISA kit

Cat#: orb438433 (ELISA Manual)

I. Introduction

Cholecystokinin (CCK) is a peptide hormone of the gastrointestinal system responsible for stimulating the digestion of fat and protein. It is synthesized by Icells in the mucosal epithelium of the small intestine and secreted in the duodenum, and causes the release of digestive enzymes from the pancreas and bile from the gallbladder. CCK is a family of hormones identified by number of amino acids depending on post-translational modification of preprocholecystokin in, including CCK58, CCK33 and CCK8. CCK is very similar in structure to another peptide hormone gastrin. They share five identical amino acids at their C-termini. CCK mediates a number of physiological processes, including digestion and satiety. Secretion of CCK by the duodenal and intestinal mucosa is stimulated by fat- or protein-rich chyme entering the duodenum. It then inhibits gastric emptying and gastric acid secretion and mediates digestion in the duodenum. It stimulates the acinar cells of the pancreas to release water and ions and stimulates the secretion of a juice rich in pancreatic digestive enzymes, hence the old name pancreozymin. Together these enzymes catalyze the digestion of fat, protein, and carbohydrates. Thus, as the levels of the substances that stimulated the release of CCK drop, the concentration of the hormone drops as well. The release of CCK is also inhibited by somatostatin. CCK also causes the increased production of hepatic bile, and stimulates the contraction of the gall bladder and the relaxation of the Sphincter of Oddi (Glisson's sphincter), resulting in the delivery of bile into the duodenal part of the small intestine. Bile salts form amphipathic micelles that emulsify fats, aiding in their digestion and absorption.

II. General Description

The Biorbyt CCK Enzyme Immunoassay (EIA) Kit is an in vitro quantitative assay for detecting CCK peptide based on the competitive enzyme immunoassay principle. In this assay, a biotinylated CCK peptide is spiked into the samples and standards. The samples and standards are then added to the plate, where the biotinylated CCK peptide competes with endogenous (unlabeled) CCK for binding to the anti- CCK antibody. After a wash step, any bound biotinylated CCK then interacts with horseradish peroxidase (HRP)-streptavidin, which catalyzes a color development reaction. The intensity of the colorimetric signal is directly proportional to the amount of captured biotinylated CCK peptide and inversely proportional to the amount of endogenous CCK in the standard or samples. A standard curve of known concentration of CCK peptide can be established and the concentration of CCK peptide in the samples can be calculated accordingly.

III. How It Works



IV. Storage

The entire kit may be stored at -20°C to -80°C for up to 6 months from the date of shipment. For extended storage, it is recommended to store at -80°C.

Avoid repeated freeze-thaw cycles. For prepared reagent storage, see table below.

V. Reagents

Component	Size / Description	Storage / Stability After Preparation
EIA Microplate (Item A)	96 wells (12 strips x 8 wells) coated with secondary antibody.	1 month at 4°C*
Wash Buffer Concentrate (20X) (Item B)	25 ml of 20X concentrated solution.	1 month at 4°C
Standard CCK Peptide (Item C)	2 vials of Lyophilized CCK Peptide. 1 vial is enough to run each standard in duplicate.	Do not store and reuse
Anti-CCK Polyclonal Antibody (Item N)	2 vials of Lyophilized anti-CCK.	Do not store and reuse
5X Assay Diluent B (Item E)	15 ml of 5X concentrated buffer. Diluent for both standards and samples including serum, plasma, cell culture media or other sample types.	1 month at 4°C
Biotinylated CCK Peptide (Item F)	2 vials of Lyophilized Biotinylated CCK Peptide, 1 vial is enough to assay half the plate.	Do not store and reuse
HRP-Streptavidin Concentrate (Item G)	600 µl 40X concentrated HRP-conjugated streptavidin.	Do not store and reuse
Positive Control (Item M)	1 vial of Lyophilized Positive Control.	Do not store and reuse
TMB One-Step Substrate Reagent (Item H)	12 ml of 3,3,5,5'-tetramethylbenzidine (TMB) in buffer solution.	N/A
Stop Solution (Item I)	8 ml of 0.2 M sulfuric acid.	N/A

*Return unused wells to the pouch containing desiccant pack, reseal along entire edge.

VI. Additional Materials Required

1. Microplate reader capable of measuring absorbance at 450 nm
2. Precision pipettes to deliver 2 µl to 1 ml volumes
3. Adjustable 1-25 ml pipettes for reagent preparation
4. 100 ml and 1-liter graduated cylinders
5. Absorbent paper
6. Distilled or deionized water
7. Sigma Plot software (or other software which can perform four-parameter logistic regression models)
8. Tubes to prepare standard or sample dilutions
9. Orbital shaker
10. Aluminum foil
11. Plastic wrap

VII. Reagent Preparation

Keep kit reagents on ice during reagent preparation steps.

A. Preparation of Plate and Anti-CCK Antibody

1. Equilibrate plate to room temperature before opening the sealed pouch.
2. Label removable 8-well strips as appropriate for your experiment.
3. 5X Assay Diluent B (Item E) should be diluted 5-fold with deionized or distilled water.
4. Briefly centrifuge the anti-CCK antibody vial (Item N) and reconstitute with 55 µl of 1X Assay Diluent B to prepare the antibody concentrate. Pipette up and down to mix gently.
5. The antibody concentrate should then be diluted 100-fold with 1X Assay Diluent B. This is your anti-CCK antibody working solution, which will be used in step 2 of Assay Procedure (Section VIII).

Note: The following steps may be done during the antibody incubation procedure (step 2 of Assay Procedure)

B. Preparation of Biotinylated CCK (Item F)

6. Briefly centrifuge the vial of Biotinylated CCK (Item F) and reconstitute with 20 µl of ddH2O before use.
7. See the image below for proper preparation of Item F. Transfer the entire contents of the Item F vial into a tube containing 5 ml of 1X Assay Diluent B. This is your Working Stock of Item F. Pipette up and down to mix gently. *The final concentration of biotinylated CCK will be* ***40 pg/ml***.
a. Second Dilution of Item F for Standards: Add 2 ml of Working Stock Item F to 2 ml of 1X Assay Diluent B. The final concentration of biotinylated CCK will be **20 pg/ml**.
b. Second Dilution of Item F for Positive Control: Add 100 µl of Working Stock Item F to 100 µl of the prepared Positive Control (Item M). (See section D for Positive Control preparation) The final concentration of biotinylated CCK will be **20 pg/ml**.
c. Second Dilution of Item F for samples: Add 125 µl of Working Stock Item F to 125 µl of prepared sample (see section E for sample preparation). This is a 2-fold dilution of your sample. The final concentration of biotinylated CCK will be **20 pg/ml**.



Biorbyt Ltd.
5 Orwell Furlong, Cowley Road,Cambridge, Cambridgeshire
CB4 0WY, United Kingdom
Email: info@biorbyt.com | Phone: +44 (0)1223 859 353 | Fax: +44(0)1223 280 240

Biorbyt LLC
Suite 103, 369 Pine Street, San Francisco
California 94104, United States
Email: info@biorbyt.com | Phone: +1 (415)-906-5211 | Fax: +1 (415) 651 8558

C. Preparation of Standards

8. Label 6 microtubes with the following concentrations: 1,000 pg/ml, 100 pg/ml, 10 pg/ml, 1 pg/ml, 0.1 pg/ml and 0 pg/ml. Pipette 450 µl of biotinylated CCK Item F working solution (prepapred in step 7a) into each tube, except the 1,000 pg/ml (leave this one empty). *It is very important to make sure the concentration of biotinylated CCK is 20 pg/ml in all standards.*
9. Briefly centrifuge the vial of CCK Standard (Item C). Reconstitute with 10 µl of ddH2O and briefly vortex if desired. Pipette 8 µl of Item C and 792 µl of 20 pg/ml biotinylated CCK working solution (prepared in step 7a) into the tube labeled 1000 pg/ml. Mix thoroughly. This solution serves as the first standard (1000 pg/ml CCK standard, 20 pg/ml biotinylated CCK).
10. To make the 100 pg/ml standard, pipette 50 µl of the 1000 pg/ml CCK standard into the tube labeled 100 pg/ml. Mix thoroughly.
11. Repeat this step with each successive concentration, preparing a dilution series as shown in the illustration below. Each time, use 450 µl of biotinylated CCK and 50 µl of the prior concentration until the 0.1 pg/ml is reached. Mix each tube thoroughly before the next transfer.



D. Positive Control Preparation

12. Briefly centrifuge the Positive Control vial (Item M) and reconstitute with 100 µl of ddH2O.
13. Refer to step 7b. This is a 2-fold dilution of the Positive Control. The final concentration of biotinylated CCK should still be 20 pg/ml. The Positive Control is a cell culture media sample that serves as a system control to verify that the kit components are working. The Positive Control may be diluted further if desired, but be sure the final concentration of biotinylated CCK is 20 pg/ml.

E. Sample Preparation

14. If you wish to perform a 2-fold dilution of your sample, proceed to step 7c. If you wish to perform a higher dilution of your sample, dilute your sample with 1X Assay Diluent B before performing step 7c.
EXAMPLE (to make a 4-fold dilution of sample):

a. Dilute sample 2-fold (62.5 µl of sample + 62.5 µl of 1X Assay Diluent B.).
b. Perform step 7c (125 µl of working solution Item F + 125 µl of sample prepared above).
The total volume is 250 µl, enough for duplicate wells on the microplate. It is very important to make sure the final concentration of the biotinylated CCK is **20 pg/ml**.
Note: Optimal sample dilution factors should be determined empirically, however you may reference below for recommended dilution factors for serum: Human=4X Mouse=4X Rat=2X.

F. Preparation of Wash Buffer and HRP

15. If Item B (20X Wash Concentrate) contains visible crystals, warm to room temperature and mix gently until dissolved.
16. Dilute 20 ml of Wash Buffer Concentrate into deionized or distilled water to yield 400 ml of 1X Wash Buffer.
17. Briefly centrifuge the HRP-Streptavidin vial (Item G) before use.
18. Dilute the HRP-Streptavidin concentrate 40-fold with 1X Assay Diluent B.

VIII. Assay Procedure

1. Keep kit reagents on ice during reagent preparation steps. It is recommended that all standards and samples be run at least in duplicate.
2. Add 100 µl of Anti-CCK Antibody (Item N) (See Reagent Preparation step 5) to each well. Incubate for 1.5 hours at room temperature with gentle shaking (1-2 cycle/sec). You may also incubate overnight at 4ºC.
3. Discard the solution and wash wells 4 times with 1X Wash Solution Buffer (200- 300 µl each). Washing may be done with a multichannel pipette or an automated plate washer. Complete removal of liquid at each step is essential to good assay performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
4. Add 100 µl of each standard (see Reagent Preparation Section C), Positive Control (see Reagent Preparation Section D) and sample (see Reagent Preparation Section E) to appropriate wells. Be sure to include a blank well (Assay Diluent only). Cover wells and incubate for 2.5 hours at room temperature with gentle shaking (1-2 cycles/sec) overnight or at 4ºC.
5. Discard the solution and wash 4 times as directed in Step 3.
6. Add 100 µl of prepared HRP-Streptavidin solution (see Reagent Preparation step 18) to each well. Incubate for 45 minutes at room temperature with gentle shaking. It is recommended that incubation time should not be shorter or longer than 45 minutes.
7. Discard the solution and wash 4 times as directed in Step 3.
8. Add 100 µl of TMB One-Step Substrate Reagent (Item H) to each well. Incubate for 30 minutes at room temperature in the dark with gentle shaking (1-2 cycles/sec).
9. Add 50 µl of Stop Solution (Item I) to each well. Read at 450 nm immediately.

IX. Assay Procedure Summary

1. Prepare all reagents, samples and standards as instructed.
2. Add 100 µl anti-CCK to each well. Incubate 1.5 hours at room temperature or overnight at 4ºC.
3. Add 100 µl standard or sample to each well. Incubate 2.5 hours at room temperature or overnight at 4ºC.
4. Add 100 µl prepared Streptavidin solution. Incubate 45 minutes at room temperature.

5. Add 100 µl TMB One-Step Substrate Reagent to each well. Incubate 30 minutes at room temperature.
6. Add 50 µl Stop Solution to each well. Read at 450 nm immediately.

X. Calculation of Results

Calculate the mean absorbance for each set of duplicate stands, controls, and samples and subtract the blank optical density. Plot the standard curve using Sigma Plot software (or other software which can perform four-parameter logistic regression models), with standard concentration on the x-axis and percentage of absorbance (see calculation below) on the y-axis. Draw the best-fit curve through the standard points.
Percentage absorbance = (B-blank OD)/ (B0-blank OD) where
B = OD of sample or standard and
B0 = OD of zero standard (total binding)

A. Typical Data
B.
These standard curves are for demonstration only. A standard curve must be run with each assay.



B. Sensitivity

The minimum detectable concentrations of CCK is 0.2 pg/ml.

C. Standard Curve Range

0.1-1,000 pg/ml

D. Reproducibility

Intra-Assay: CV<10%
Inter-Assay: CV<15%

E. Assay Diagram

Recommended Plate Layout:

Blank	Blank	SA1	SA1	SA9	SA9	SA17	SA17	SA25	SA25	SA33	SA33
Total Binding	Total Binding	SA2	SA2	SA10	SA10	SA18	SA18	SA26	SA26	SA34	SA34
Standard1	Standard1	SA3	SA3	SA11	SA11	SA19	SA19	SA27	SA27	SA35	SA35
Standard2	Standard2	SA4	SA4	SA12	SA12	SA20	SA20	SA28	SA28	SA36	SA36
Standard3	Standard3	SA5	SA5	SA13	SA13	SA21	SA21	SA29	SA29	SA37	SA37
Standard4	Standard4	SA6	SA6	SA14	SA14	SA22	SA22	SA30	SA30	SA38	SA38
Standard5	Standard5	SA7	SA7	SA15	SA15	SA23	SA23	SA31	SA31	SA39	SA39
Pos Control	Pos Control	SA8	SA8	SA16	SA16	SA24	SA24	SA32	SA32	SA40	SA40

Key:
Blank = Buffer Only
Total Binding = Biotin-CCK only
Standard 1 = 1000 pg/ml
Standard 2 = 100 pg/ml
Standard 3 = 10 pg/ml
Standard 4 = 1 pg/ml
Standard 5 = 0.1 pg/ml
Pos Control = Biotin with Item M

XI. Specificity

Cross Reactivity: This EIA kit shows no cross-reactivity with any of the cytokines tested: Ghrelin, Nesfatin, NPY and APC.

XIV. Publications Citing This Product

1. Miyamoto S, Shikata K, Miyasaka K, et al. Cholecystokinin Plays a Novel Protective Role in Diabetic Kidney Through Anti-inflammatory Actions on Macrophage: Anti-inflammatory Effect of Cholecystokinin. Diabetes 2012;61(4):897-907. doi:10.2337/db11-0402.

Species: Rat
Sample Type: Serum

2. Zhou L., Yang H., Lin X., et al. Cholecystokinin Elevates Mouse Plasma Lipids. December 21, 2012. DOI: 10.1371/journal.pone.0051011

Species: Mouse
Sample Type: Plasma

3. Zhou L, Yang H, Lin X, Okoro EU, Guo Z (2012) Cholecystokinin Elevates plasma Lipids. PLoS ONE 7(12): e51011. doi:10.1371/ journal.pone.0051011

Species: Mouse
Sample Type: Plasma

XIII. Troubleshooting Guide

Problem	Cause	Solution
Poor standard curve	• Inaccurate pipetting • Improper standard dilution	• Check pipettes • Briefly centrifuge Item C and dissolve the powder thoroughly by gently mixing
Low signal	• Improper preparation of standard and/or biotinylated antibody • Too brief incubation times • Inadequate reagent volumes or improper dilution	• Briefly spin down vials before opening. Dissolve the powder thoroughly. • Ensure sufficient incubation time; assay procedure step 2 may be done overnight • Check pipettes and ensure correct preparation
Large CV	• Inaccurate pipetting • Air bubbles in wells	• Check pipettes • Remove bubbles in wells
High background	• Plate is insufficiently washed • Contaminated wash buffer	• Review the manual for proper wash. If using a plate washer, ensure that all ports are unobstructed. • Make fresh wash buffer
Low sensitivity	• Improper storage of the ELISA kit • Stop solution	• Follow storage recomendations in sections IV and V. Keep substrate solution protected from light. • Add stop solution to each well before reading plate

Biorbyt Ltd.
5 Orwell Furlong, Cowley Road,Cambridge, Cambridgeshire
CB4 0WY, United Kingdom
Email: info@biorbyt.com | Phone: +44 (0)1223 859 353 | Fax: +44(0)1223 280 240

Biorbyt LLC
Suite 103, 369 Pine Street, San Francisco
California 94104, United States
Email: info@biorbyt.com | Phone: +1 (415)-906-5211 | Fax: +1 (415) 651 8558